Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative

Pediatric Blood and Cancer

Volumn 51, Issue 6, 2008, Pages 828-831

  Colavolpe, Cécile ^a,b   Guedj, Eric ^a   Cammilleri, Serge ^a   Taïeb, David ^a   Mundler, Olivier ^a   Coze, Carole ^a  

^a University Hospital   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Fluorine 18 fluorodeoxyglucose; I123 MIBG; Neuroblastoma; Positron emission tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; RETINOIC ACID; TOPOTECAN; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INFANT; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY;

3-IODOBENZYLGUANIDINE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; INFANT; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEUROBLASTOMA; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 56749107480     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21594     Document Type: Article

References (20)

1. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
2. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumor Working Party. Eur J Cancer 1997;33:2130-2135.
3. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2081-2091.
4. Bombardieri E, Aktolun C, Baum RP, et al. 131I/123I Metaiodobenzylguanidine (MIBG) scintigraphy: Procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging 2003;30:BP132-BP139.
5. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-688.
6. Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med 2003;47:31-40.
7. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-2491.
8. Shulkin BL, Hutchingson RJ, Castle VP, et al. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-750.
9. Kushner BH, Yeung HWD, Larson SM, et al. Extending PET scan utility to high-risk neuroblastoma: 18F-Fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-3405.
10. Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology 1995;194:495-500.
11. Wahl RL, Hutchins GD, Buchsbaum DJ, et al. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991;67:1544-1550.
12. Kushner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172-1188.
13. Nanni C, Rubello D, Castellucci P, et al. 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumors. Biomed Pharmacother 2006;60:593-606.
14. Minard V, Hartmann O, Peyroulet MC, et al. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: Results of the French society of pediatric oncology. Br J Cancer 2000;83:973-979.
15. Iavarone A, Lasorella A, Servidei T, et al. Uptake and storage of miodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 1993;53:304-309.
16. Montaldo PG, Carbone R, Ponzoni M, Cornaglia-Ferraris P. Gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Res 1992;52:4960-4964.
17. Heyman S, Evans AE, D'Angio GJ. I-131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapse. Med Pediatr Oncol 1988;16:337-340.
18. Adams S, Baum RP, Hertel A, et al. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumors: Comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998;19:641-647.
19. Brans B, Laureys G, Schelfhout V, et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: Lack of relation to tumor differentiation in vivo. Eur J Nucl Med 1998;25:144-149.
20. Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-521.